Eplontersen clinical trials
Also written ION-682884 and IONIS-TTR-LRx.
How each study uses eplontersen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the eplontersen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Dec 2023 · WAINUA (AUTOINJECTOR) · NDA 217388 (FDA, Drugs@FDA)
- European Union
- 6 Mar 2025 · Wainzua · EMEA/H/C/006295 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 1
Ionis Pharmaceuticals, Inc. (6) · AstraZeneca (2) · Brigham and Women's Hospital (1)
Studies
Open first, then newest update. How each study uses eplontersen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)Enrolling by invitationPhase 3Ionis Pharmaceuticals, Inc.NCT05667493Written as Eplontersen
- EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid CardiomyopathyActive, not recruitingPhase 3AstraZenecaNCT06194825Written as Eplontersen
- CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)CompletedPhase 3Ionis Pharmaceuticals, Inc.NCT04136171Written as Eplontersen
- ION-682884 in Patients With TTR Amyloid CardiomyopathyWithdrawnPhase 2Brigham and Women's HospitalNCT04843020Written as ION 682884
- A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid PolyneuropathyActive, not recruitingPhase 3Ionis Pharmaceuticals, Inc.NCT05071300Written as Eplontersen
- NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid PolyneuropathyCompletedPhase 3Ionis Pharmaceuticals, Inc.NCT04136184Written as Eplontersen
- A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese VolunteersCompletedPhase 1AstraZenecaNCT06527755Written as Eplontersen Solution for Injection
- Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).CompletedPhase 1/2Ionis Pharmaceuticals, Inc.NCT03728634Written as ION-682884
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese ParticipantsCompletedPhase 1Ionis Pharmaceuticals, Inc.NCT04302064Written as Eplontersen
Given beside what is tested · 1 — eplontersen is usual care or a partner of the new treatment
Codes
What other systems call eplontersen · ClinicalTrials.gg INT002093
- MeSH (NLM) C000730926eplontersenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 0GRZ0F5XJ6EPLONTERSENConfirmed FDA, NLM, Wikidata
- Wikidata Q123663227eplontersenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C175062EplontersenOne source FDA
- DrugBank DB16199One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000730926 | eplontersen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 0GRZ0F5XJ6 | EPLONTERSEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123663227 | eplontersen | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C175062 | Eplontersen | One source FDA |
| DrugBank | DB16199 | — | One source Wikidata |
Also registered as eplontersen sodium (UNII WSP2DHR2BD).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.